She also gained administrative and client services experience in roles she held at Life Time Athletic, EF Education First, and at Beth Israel Deaconess Hospital ICU. Tyler holds a BA in Finance from the University of Massachusetts, Amherst and a certificate in Interactive Design from Rhode Island School of Design. He worked previously as a Patient Coordinator at Massachusetts General Hospital. Christys primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Jesse Chen is an EIR at RA Capital. Gunes holds a BSc in Biological Sciences and Bioengineering from Sabanci University, a MSc in Molecular and Cellular Biology and a PhD in Biochemistry from the University of Heidelberg. Davids primary responsibility is to oversee the development and implementation of treasury functions for the firm. In his Venture role, Mario is focusing on early-stage investment and company creation. Prior to MRL Ventures, Josh was a Venture Partner with Atlas Venture and a Partner at Prism Venture Partners, focusing on company formation and seed and Series A investing. Prior to this role, Cristina mapped a number of competitive landscapes, including respiratory, allergic, and infectious disease conditions. Kriti previously served as Co-Director and Regional Director, South Asia for MIT Hacking Medicine. He is co-founder and CEO of Clear Creek Bio, an RA Capital portfolio company. Her primary responsibility is leading and executing full cycle recruiting across all newcos and portfolio companies. Alyssa Larson is an Associate Director within the TechAtlas division at RA Capital Management. Prior to RA Capital, Tyler worked as a freelance graphic designer. He works closely with RA's Investment Team on novel drug discovery platforms with emphasis on computational chemistry and machine learning. He was previously a marketing manager at Brighton House Associates, assisting with fundraising campaigns for a diverse group of investment managers, including private equity, venture capital, real estate, and hedge funds. Most importantly, this book describes concrete . Prior to Mintz, Kate held a Paralegal role at Loughran & Corbett, Attorneys, Inc. Kate holds a Bachelor's Degree in Political Science from Bridgewater State University and is a certified Paralegal in Massachusetts. Kevin Grosselin is RA Ventures Associate at RA Ventures (RAVen). Prior to joining the team at Enara Sophie was a medical oncologist at Guys and St Thomas NHS Foundation Trust in London, UK (GSTT). Nate conducts due diligence on biotechnology companies at RA Capital and serves as a Board Director for The Covid Apollo Project and Nucleix. Prior to Acceleron, Habib held various leadership roles at Bayer AG during his ~22-year tenure with the company. Anas primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Craig is admitted to practice law in the Commonwealth of Massachusetts. Mario is a Venture Partner and Head of Vaccines at RA Capital. Asthas primary responsibility is to identify needs for process improvement in the firm's data analytics and then both build and implement automated solutions. Prior to Proteros, Cony was Senior Vice President, Business Development, North America for Evotec and was responsible for managing all commercial activities of Evotec in North America. Gerald holds a PhD in Molecular and Cellular Biology from Harvard Medical School. Many of the assets he contributed to within HNDC have been out-licensed to various Cambridge and Boston-based startups and biotech firms for further development. Prior to IGEN Cony worked for Corning in the US and in Europe. Mariagrace Houllahan is an Executive Assistant at RA Capital Management. Tess works on both public and private investments and serves on several company boards. He was named an MIT Technology Review 100 innovators under 35 for his MIT Media Lab social enterprise, Dimagi, that has impacted millions with its mobile data collection platform. Robert Nicol is a Venture Partner at RA Ventures (RAVen), focusing on company creation. Peter Pan & Wendy Movie Review | Common Sense Media He was Vice President of Merck business development and licensing where he led BD activities in the US (West Coast), Europe, and Asia Pacific region, as well as President of MRL Ventures where he led equity investing in early-stage therapeutics companies. Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. Candice previously worked as the Director of Executive Office and Administration at Flywire. Mariagrace previously worked as an Executive Assistant at MPM Capital. His primary responsibilities are to assist with accounting, financial reporting and investment valuation. RA Capital makes no guarantees as to their accuracy or completeness. Brian's primary responsibility at RA Capital is to manage the firm's IT Operations needs. Jake Simson is a Partner at RA Capital Management. He holds an MD magna cum laude from Harvard-MIT, Program in Health Sciences and Technology, where he was a Paul and Daisy Soros Fellow. Early in his career, Mr. Grau worked with multi-national pharma companies including Pharmacia, Pharmacia & Upjohn, and Eisai as a management consultant focused on corporate strategy, M&A, and new product launch. What is Peter Kolchinsky Net Worth? Pieter has been recognized as one of the outstanding leaders in the U.S. through his selection as a White House Fellow, and he currently serves on the Board of Directors of the White House Fellows Foundation. James has over 25 years of industry experience in creating and building biotechnology companies including experience as a co-founder of the lysosomal storage diseases company Vtesse acquired by Sucampo/Malinkrodt, co-founder of the clinical stage neuroendocrine company Tiburio, Board Director of the ocular gene therapy company Nightstar acquired by Biogen, and as founding Chief Scientific Officer of the rheumatology therapy company Synovex/Adheron acquired by Roche. Nadim has 11+ years experience in commercializing drug discovery across diverse indications and modalities. Lauras primary responsibilities at RA Capital are to coordinate calendars, events, and company meetings for the TechAtlas division. Semper Maior: Time to Reboot Biotech RApport Peter Kolchinsky - Managing Partner - RA Capital Management, LP - LinkedIn Cosmass academic research has been published in journals such as Cell, Science, and Nature. Kats primary responsibility is supporting newcos, portfolio companies and executives within RAVen, focusing on strategic finance. Tom holds a BS in Health Sciences with a minor in Journalism from Northeastern University. Megan Lipcsey is an Associate with the TechAtlas division of RA Capital Management. He previously worked as a Software Engineer for several companies, including Autodesk, the Advisory Board Company, and Maveric Systems. Daniels primary responsibilities include creating competitive landscapes of climate change solutions and analyzing investment opportunities across climate technology and applied biotech. Sonias primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Danielle Feldman is the Director of Corporate Development at Aliada Therapeutics. Shan Shans primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Henry has a BA in Biology & Economics from Dartmouth College. Barrie's 1911 novel. In addition, Cosmas has co-founded companies including Design Pharma (synthetic bio) and a company in stealth focused on RNA based genetic medicines. Rezs primary responsibility is to lead early-stage private investments in, and oversee the creation of, new companies developing therapeutics and other medical technologies. Mario is responsible for partnering with several of our portfolio companies as Board Member or Technical Advisor. He is the co-inventor of first-in-class HCV NS5A inhibitors, which led to the approval of DaklinzaTM, the first marketed drug in its class. He had to juggle the demands of raising a family while also trying to pay for his children's education. Raj previously worked as a Senior Project Leader at Altus Pharmaceuticals, a spin-off company of Vertex Pharmaceuticals, where he assessed business processes and implemented system solutions across all areas of science. In this position, he played a critical role in building Mercks oncology pipeline into one of the most robust in cancer immunotherapy, focusing on a modality-agnostic strategy with a broad biology of targets and Keytruda combination strategies. Peter Kolchinsky on Twitter Mike is President and Chief Executive Officer of Sionna. He holds a BA in Environmental Engineering from Dartmouth College (1998), an MA in International Finance and Energy Policy from John Hopkins University (2008), an MS in Materials Science from Columbia University (2012), and a Masters of Strategic Studies from the Army War College (2020). He was also the co-founder and President of Research and Development of Cydan, a rare disease accelerator. Prior to Indigo, Kathryn was Investment Principal at the Massachusetts Clean Energy Center (MassCEC) where she invested in enterprise and consumer-facing clean energy companies, including software and hardware companies focused on utility and grid resilience, grid edge, next-generation renewables, efficient mobility, industrial efficiency, sustainable buildings, and the water-energy nexus. In this role, he works closely with the RA Venture team to evaluate and incubate early-stage therapeutic programs. Prior to RA, he served in a dual role at Merck Research Laboratories (MRL). Kate previously served as Health Law Assistant at Mintz. Sarah earned her BA from Harvard College in East Asian Studies and her JD from Harvard Law School. Daniels primary responsibility at RA Capital is to edit and guide development of competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Erin holds a Bachelor of Fine Arts degree from the Massachusetts College of Art & Design. Peter served on the Board of Global Science and Technology for the National Academy of Sciences and writes about the biotech social contract. He also served as member of the Product Advisory Board at Concert Pharmaceuticals and as an Advisor to Nimbus Therapeutics. 4. Her primary responsibilities are to support our Venture Team by coordinating management agendas, calendars, and external events. His graduate research focused on identifying novel targets for disrupting the cell cycle in cancer cells. Henry Stusnick is an Associate at RA Capital Management. Adisons primary responsibilities are to coordinate calendars, events, and company meetings for the Investment Team. Erich Scheller is the Director of the TechAtlas division of RA Capital Management. Jeff holds a BA in Economics and Psychology from Georgetown. Emily has her BS in Chemical Engineering from Rensselaer Polytechnic Institute in NY. Mariagrace has a BS in Sociology from Suffolk University. Most recently, Brendan served as Tax Director at PwC Asset & Wealth Management. Brian has a B.S. Peter Kolchinsky - Biography - MarketScreener.com Previously, Rebecca worked as a Senior Associate within RAs TechAtlas division. Prior to RA, Christy was a Senior Scientist in Oncology Target Discovery at Pfizer. Angela's primary responsibilities at RAVen are to lead development and oversee implementation of best practices in clinical strategies in RA's newcos and portfolio companies. Milind Deshpande is a Venture Partner at RA Capital, and President & CEO of Nayan Therapeutics, a RA Capital portfolio company. Phi previously worked as an Executive Assistant at Relay Therapeutics. As a founder and member of Constellations executive team Patrick materially contributed to several successful financing rounds and deals, including a crossover round, an IPO and the ultimate acqusition of the company. Previously, Jake covered solid tumor oncology landscapes. Matthew holds a BS in Environmental Health Science from the University of Georgia and both a PhD in Biomedical Science and an MBA with a concentration in Finance from the University of Connecticut. In that role, Joel led teams responsible for advancing more than 40 compounds into clinical development, including Sprycel (dasatinib), which he co-invented. She works with RAs newcos to develop optimal pitch decks and public messaging, authors articles, and runs the firms internal and external business courses. Pathways to | Harvard Office of Technology Development Her graduate research investigated synaptic translation in syndromic autism. Most recently, he was Chief Technology Officer at Vor Bio where he built the technical operations team responsible for process development, analytical development, supply chain and manufacturing support of a CRISPR gene-edited HSPC product and oversaw the companys CAR-T efforts. 'Too old': 80-year-old Biden works to combat worries about his age in He has held multiple senior level clinical development positions including Chief Medical Officer at Asceneuron SA and Neurodegeneration Therapeutic Area Head at Novartis. He holds a BA in History from University of Massachusetts, Amherst and a Master's of Urban Affairs from Boston University. Matts primary responsibilities at RA Capital are to gather team input to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities, and to provide software training and coordinate with outside technology vendors. in Neuroscience from University of Pennsylvania and a PhD in Neuroscience from University of Oxford. Dan Guglielmo is IT Operations Associate at RA Capital Management. Prior to RA, Ryan was at KPMG where he was a Senior Associate. Scott received his Bachelor of Science from the University of Illinois and his Ph.D. from the Massachusetts Institute of Technology. Eric holds a MAcc from Bentley University and a BS in Finance from George Mason University. Harvey most recently served as Assistant Controller at Charles River Ventures. Drinking, Drugs & Smoking Not present. Garrett has worked cross-functionally across the landscape of in vivo and ex vivo genetic medicine modalities, often at the interface of payload design, platform research and manufacturing, IND-enabling activities, bioanalytical and computational biology, and strategy. Phi's primary responsibilities at RA Capital are to support the Operations team by coordinating calendars, events, and company meetings. He holds a BA from Cornell University and a PhD in Virology from Harvard University. David holds a BS in Economics with a minor in Business Administration from University of Colorado Boulder. Prior to joining RA, Jesse was Senior Director of Discovery at Kymera Therapeutics. Prithviraj works on both public and private investments with a focus on Healthcare, Technology, and Services. Ryan Russell is a Fund Accountant at RA Capital Management. Kevin has a ME in Chemistry and Chemical Engineering from Chimie ParisTech in France, a MS in Biotechnology from the Royal Institute of Technology in Sweden, and a PhD in Physics and Chemistry from Paris Sciences et Lettres Research University in France. Priscilla Lee is an Associate within the TechAtlas division of RA Capital Management. Natalie brings to RAVen more than six years of Administrative experience. The Great American Drug Deal | Peter Kolchinsky, PhD - NetGalley He is also an active member of the Big Brothers of Massachusetts Bay program. Peter is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools and serves on the boards of publicly- and privately-held life science companies. Sri Mahendra is a Senior Software Engineer at RA Capital Management. Vanderpump Rules: How Old Is Peter Madrigal? - Screen Rant Laura Stoppel is a Principal on the Investment Team at RA Capital Management. She received a B.Sc. This helps us to provide you with a good experience when you browse our website, and also allows us to improve our site. Her doctoral research focused on bacteriophage-mediated regulation of bacterial transcription. Sadik Kassim is a scientist and executive with extensive experience in the biotechnology industry with a specific focus on cell and gene therapy bioprocessing and translational research. Joel brings 40 years of BioPharma drug discovery and development experience to that role. RA Capital and CEO of Arcuate Therapeutics. Brendan is a Tax Director at RA Capital Management. Adam has 20+ years of industry experience in building healthcare and technology companies, including as CEO and co-founder of Link Medicine, a company focused on developing disease-modifying neurodegenerative therapies and as CEO and co-founder of Teleos Therapeutics, an innovative neuroscience drug discovery platform company. Neil has spent five years at RA Ventures where he was most recently Vice President, CMC and worked across new company formation and in support of portfolio companies. After leaving Schrodinger in 2018, Soumya founded 3-Dimensional Consulting, a boutique Physics Based and Machine-Learning focused computational chemistry consulting firm that provides scientific support for early-stage drug discovery and company formation within various Boston-based venture firms including: Atlas Venture, 3rd Rock, MPM Capital, and RA Capital. Abhishek gained experience using data analytics to track and visualize patient testing in his most recent role at Blueprint Medicines. Alonso Ricardo is an Entrepreneur in Residence at RA Capital, where he works closely with RAs Venture Team to evaluate drug discovery platforms and initiate novel therapeutics programs. Kathryn has a BS in Exercise and Health Science from the University of Massachusetts Boston. Vikram studied engineering at the Indian Institute of Technology, Delhi before earning a BS in Operations Research with honors from Columbia University. Matts primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Soumya completed his postdoc at Brigham and Womens Hospital and held an Assistant Professor of Neuroscience role at Harvard Medical School Neurology Department where he contributed to the Harvard Neurodiscovery Centers (HNDC) academic drug discovery initiative as a modeler and drug hunter. Cristina holds a Bachelor of Arts in Biochemistry from Mount Holyoke College and a PhD in Cell Biology and Epigenetics from Cornell University and The Rockefeller University. Rez Halse is President of RAVen, also known as RA Ventures, RA Capitals company creation incubator. Garrett received a BS with honors from the California Institute of Technology while publishing his first paper with Dr. Paul H. Patterson, holds a PhD in Immunology from Stanford University, where he studied hematopoietic stem and progenitor cells with Dr. Irving L. Weissman, and completed his post-doctoral training at Childrens Hospital Boston/Harvard Medical School studying ES/iPSC specification to the hematopoietic fate with Dr. George Q. Daley. Jacqueline is an Associate, Strategic Finance at RA Capital Management. Merediths primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. At Prevail, Emily led business functions including business development, strategy, commercialization, public relations, patient advocacy, and intellectual property, and co-led financings generating $250 million in proceeds, including the companys IPO in 2019. Kate holds a BA in Molecular Biology and Biochemistry from Rutgers University, and a PhD in Biochemistry from MIT. Robert also led the Sequencing Operations and Technology Development groups at the Broad for over 12 years, implementing industrial process control methods, developing multiple generations of high-throughput DNA sequencing technologies, and establishing an agile learning culture in the organization. Alonso completed his Ph.D. in Chemistry at the University of Florida and his post-doctoral work as a Howard Hughes Medical Institute Fellow at Harvard University and the Massachusetts General Hospital. PETER KOLCHINSKY, PhD Managing Partner RAJEEV SHAH Managing Partner ANDREW LEVIN, MD/PhD Partner and Managing Director JOSH RESNICK, MD Senior Managing Director PETER BALOGH Analyst GUNES BOZKURT, PhD Analyst TESS CAMERON Principal NATE DAVIS Analyst DEREK DiROCCO, PhD Partner CRISTINA GHENOIU, PhD Principal MICHAEL GILLESPIE, MD Analyst Prior to joining RA Capital, Jeff worked for over 10 years as an institutional equity sales trader, primarily at KCG Holdings, Inc., where he managed the Boston office. Emilies primary responsibility at RA Capital is to manage current and potential investor relationships. Copyright 2001-2023 RA Capital Management, L.P. Mr. Grau earned his BA with High Honors from Davidson College, where he was awarded a Dana Honor Scholarship and elected to Phi Beta Kappa, and his MPhil, MA, and MAR degrees from Yale University, where he was awarded the Day Graduate Prize and was the recipient of a Mellon Fellowship in the Humanities. Brendan holds a MS in Accounting with a concentration in Taxation from Merrimack College and a BA in Economics from University of Massachusetts Amherst. Jacqueline has a BS with a double major in Molecular and Cellular Biology & Earth and Planetary Sciences from Johns Hopkins University. Prior to Baupost, he spent over five years as a Controller at Centerbridge Partners, LP, where he was responsible for accounting and valuation for the credit fund business, as well as the management company (US and Europe) and associated functions. Chris primary responsibility at RA Capital is to oversee the firms information technology program, including operations, development, and security. Kolchinsky is a founder and Managing Partner of RA Capital Management, L.P., a multi-stage investment manager which is dedicated to evidence-based investing in healthcare and life science companies that are developing drugs, medical devices, and diagnostics, where he has worked since 2001. Prior to Avilar, Mr. Grau was CEO at Sojournix, President at Heptares Therapeutics (acquired 2015), CEO at Cortria (acquired 2010), and COO at CombinatoRx (IPO 2005). All rights reserved. Milind has more than 25 years of leadership and operational experience through all stages of drug discovery and development. Cosmas Giallourakis is a Venture Partner at RA Ventures, focusing on new company creation. January 3, 2023 Feb 10th, Ed. Mario received postdoctoral training at the NIH and Mount Sinai School of Medicine in innate immunity and bioinformatics, earned a PhD in microbiology at University of Chile and a MS in Nuclear Physics. At Ra Pharma, Alonso held various leadership roles where he initiated and led the scientific efforts for the company in multiple preclinical and clinical programs; working in a wide set of therapeutic areas and using different molecular modalities. By continuing, you accept the use of these cookies. Peter Kolchinsky was born at a key point in their lives. Monicas primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Monica Stanciu is an Associate Director within the TechAtlas division at RA Capital Management. Peter Kolchinsky | Greenwich Economic Forum Prior to joining RA, Nadim was at NYU School of Medicine as Associate Dean of Therapeutics Alliances, a drug discovery accelerator that de-risks academic research towards partnerships with biopharma, investors, and nonprofits. Abhishek is a Data Analyst Associate at RA Capital Management. Anurag Kondapalli is a Principal on the Investment Team at RA Capital Management. Vikram Sheel Kumar is a Venture Partner at RA Capital where he is applying software to develop drugs and new ventures.
Ein Only Business Credit Cards No Personal Guarantee, The Scheduler Failed To Assign Job To The Runner, Chances Of Chemical Pregnancy With Pgs Normal Embryo, Skeezix Urban Dictionary, Why Did Leslie Mouton Leave Ksat 12, Articles P